Heparin-resistance in AL amyloidosis: a case report

BMC Anesthesiol. 2023 Jun 21;23(1):217. doi: 10.1186/s12871-023-02147-4.

Abstract

Background: Non-AT-III mediated heparin-resistance during CPB occurs by complex-forming with heparin-binding proteins. Currently, there are no specific recommendations for non-AT-III mediated heparin-resistance.

Case presentation: We present a fatal case of a 70-yr-old male-patient undergoing cardiac-surgery in which refractory heparin-resistance was observed. The massive AL amyloidosis found at autopsy is thought to be responsible and illustrates that awareness and knowledge of the etiology and perioperative strategies of non-AT-III mediated heparin-resistance is important.

Conclusion: For anticoagulation during cardiopulmonary bypass surgery in case of a non-AT-III medicated heparin resistance, we refer to the decision tree added to this manuscript and if necessary to consider direct thrombin inhibitors, such as bivalirudin or argatroban, as it bypasses the complexing pathway.

Keywords: AL amyloidosis; Anticoagulation; Case report; Heparin Resistance; Perfusion.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / therapeutic use
  • Cardiac Surgical Procedures*
  • Cardiopulmonary Bypass
  • Heparin / therapeutic use
  • Humans
  • Immunoglobulin Light-chain Amyloidosis* / drug therapy
  • Peptide Fragments

Substances

  • Heparin
  • Anticoagulants
  • Peptide Fragments